好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2015 Annual Meeting | 2HC.001 - Infectious, Paraneoplastic, Autoimmune? Diagnosis and Treatment of Rapidly Progressive Encephalopathies

Sunday 04/19/15
08:00 AM - 12:00 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Half-Day Course
Jeffrey M. Gelfand, MD, MAS, FAAN
Neuro-oncology
Participants should become familiar with the differential diagnosis of infectious, autoimmune, and paraneoplastic encephalopathies, the rational use of antibody testing and infectious disease diagnostics in encephalitis, and strategies for using immunosuppression as empiric treatment for autoimmune and paraneoplastic encephalitis.
3.75 CME credits
Patient Care & Procedural Skills, Medical Knowledge
Subspecialty in Focus
Trainee, General Neurologist, Specialist Neurologist, Advanced Practice Provider
Didactic
Event Timeline
08:00 AM - 08:10 AM Introduction
Jeffrey M. Gelfand, MD, MAS, FAAN
08:10 AM - 08:50 AM Diagnosis and Management of Acute Viral Encephalitis
Kenneth L. Tyler, MD, FAAN
08:50 AM - 09:05 AM Questions and Answers
Kenneth L. Tyler, MD, FAAN
09:05 AM - 09:45 AM Paraneoplastic Encephalitis
Sean J. Pittock, MD, FAAN
09:45 AM - 10:00 AM Questions and Answers
Sean J. Pittock, MD, FAAN
10:00 AM - 10:15 AM Break
10:15 AM - 10:55 AM Autoimmune Encephalitis
Josep O. Dalmau, MD, PhD, FAAN
10:55 AM - 11:10 AM Questions and Answers
Josep O. Dalmau, MD, PhD, FAAN
11:10 AM - 11:45 AM Immunosuppression for Treatment of Autoimmune and Paraneoplastic Encephalopathies
Jeffrey M. Gelfand, MD, MAS, FAAN
11:50 AM - 12:00 PM Questions and Answers
Jeffrey M. Gelfand, MD, MAS, FAAN
Faculty Disclosures
Jeffrey M. Gelfand, MD, MAS, FAAN Dr. Gelfand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities.
Sean J. Pittock, MD, FAAN Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys Therapeutics. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arialys. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from NIH. The institution of Dr. Pittock has received research support from Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from F. Hoffman/LaRoche/Genentech. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.
Josep O. Dalmau, MD, PhD, FAAN Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas Research Institute of America. Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Research & Development . Dr. Dalmau has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. An immediate family member of Dr. Dalmau has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Dalmau has received research support from Sage Therapeutics. The institution of Dr. Dalmau has received research support from Edmond J.Safra Foundation . The institution of Dr. Dalmau has received research support from La Caixa Foundation. The institution of Dr. Dalmau has received research support from Spanish Ministry of Health (ISCIII). The institution of Dr. Dalmau has received research support from Euroimmun, Inc. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care.
Kenneth L. Tyler, MD, FAAN Dr. Tyler has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Protagonist Therapeutics, Newark CA. Dr. Tyler has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Neurological Association/Wiley. Dr. Tyler has received intellectual property interests from a discovery or technology relating to health care. Dr. Tyler has received publishing royalties from a publication relating to health care. Dr. Tyler has a non-compensated relationship as a Director (ex officio) with American Neurological association that is relevant to AAN interests or activities. Dr. Tyler has a non-compensated relationship as a Director with International Society for Neurovirology that is relevant to AAN interests or activities.